150
Participants
Start Date
June 1, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
EndeavorRx
EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
Akili Interactive Labs, Inc., Boston
Akili Interactive Labs, Inc.
INDUSTRY